Kybella for the Treatment of Flank Fat (FF)

Status Completed

Clinical Trial Summary

To Determine the safety and Effectiveness of Kybella for the treatment of Flank Fat (FF)

Clinical Trial Description

This is a single center study of the safety and efficacy of Kybella for the treatment of subcutaneous adipose in the flank area (flank fat). Each qualified subject will undergo treatment with Kybella in the flank region for the reduction of flank fat.. Prior to treatment, the principal investigator will evaluate the severity of the subcutaneous adipose deposition of the flanks. Subjects will also have an MRI of the flanks at screening and week 12. .. Flank digital images will be taken prior to treatment and at each subsequent visit. The subjects will complete a safety and injection site response (ISR) diary beginning on the evening of treatment. The subjects will return at Week 6 for additional treatment if warranted by the treating investigator. Subjects will be contacted via a phone call within 72 hours after each injection. Subjects will be seen at Week 6, 10, 12 and 18 (EOS) after initial treatment, at which time the subject will undergo photography and the investigator will rate treatment improvement (GAIS). The investigator will evaluate the treatment area for any adverse events (AEs). MRI study will be done at screening and at week 12. The subject will return 6 weeks after initial treatment, and the principal investigator will determine if a touch-up treatment is warranted. If deemed necessary, a touch-up treatment may be administered Digital photography will be captured prior to treatment and following treatment. The subject will return 4 weeks after the touch-up to undergo digital photography and for the principal investigator to assess safety/improvement. After initial treatment routine follow-up visits for safety and effectiveness will occur at Week 6, 10, 12, and 18 (EOS). A phone call will occur within 72 hours following injection. At all follow-up visits, digital photography will be captured and the investigator will rate treatment improvement (GAIS).. At screening and at Week 6, 10, 12 and 18 (EOS) subjects will complete the satisfaction of flank region questionnaire. The goal of this study will be to assess the feasibility and efficacy of injecting Kybella for the treatment of subcutaneous fat of the flank region. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04841551
Study type	Interventional
Source	Beer, Kenneth R., M.D., PA
Contact
Status	Completed
Phase	Phase 4
Start date	July 22, 2021
Completion date	March 2, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05486338` - Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy	N/A
Active, not recruiting	`NCT02558920` - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Recruiting	`NCT04098679` - Childhood Adiposity and Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes (CONCEPTT Kids)
Terminated	`NCT03631680` - The Role of Estrogen in Adipocyte Remodeling Following Surgical Menopause
Not yet recruiting	`NCT04096404` - Gene-based Personalised Diet and Physical Activity Advice on Adiposity Indices Personalised Diet and Physical Activity Advice on Adiposity Indices in University Students	N/A
Completed	`NCT02975258` - Adiposity and Airway Inflammation in HIV-Associated Airway Disease	N/A
Enrolling by invitation	`NCT01971840` - Effectiveness of a Physical Activity Intervention on Preventing Obesity During the Adiposity Rebound Period.	N/A
Completed	`NCT02151825` - Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects	N/A
Recruiting	`NCT05992688` - The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)	N/A
Active, not recruiting	`NCT03575897` - Serial Assessment of Body Fat Accrual in Very Preterm Infants	N/A
Completed	`NCT03642223` - Central and Peripheral Adiposity and Iron Absorption	N/A
Active, not recruiting	`NCT03542370` - Umbrella Review of the DASH Dietary Pattern and Cardiometabolic Risk
Completed	`NCT03898518` - The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls	N/A
Recruiting	`NCT05324488` - Diabetes Registry Graz for Biomarker Research
Completed	`NCT02654535` - Meta-analyses of Nuts and Risk of Obesity
Completed	`NCT01922791` - Nutrition and Pregnancy Intervention Study	N/A
Recruiting	`NCT02041039` - REWARD SYSTEM RESPONSES TO FOOD AROMAS
Completed	`NCT03219125` - Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women
Recruiting	`NCT05433688` - Study on the Performance of Symmcora® Mid-term Suture Versus Novosyn® Suture in Patients Undergoing Robotic Assisted Gastric Bypass Surgery
Active, not recruiting	`NCT05654051` - The SLIM LIVER Study	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.